Generex Oral-lyn Phase III patient screening starts
The patient screening process for the Phase III program of the Generex Biotechnology’s oral insulin spray Generex Oral-lyn has been started in North America. The company is expected to enroll 750 patients suffering from Type 1 diabetes mellitus. The company intends to use the study to compare Generex Oral-lyn and the RapidMist diabetes management system with usual insulin therapy.
- Generex receives price approval for Oral-lyn
- FDA nod to ProStrakan’s Sancuso
- FDA approves Duramed’s LoSEASONIQUE(R) oral contraceptive
- Court invalidates Yasmin patent
